Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS

Neurology

Volumn 57, Issue 7, 2001, Pages 1239-1247

  Zivadinov, R ^a,c   Rudick, R A ^b   De Masi, R ^a   Nasuelli, D ^a   Ukmar, M ^a   Pozzi Mucelli, R S ^a   Grop, A ^a   Cazzato, G ^a   Zorzon, M ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; BRAIN ATROPHY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035833931     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.7.1239     Document Type: Article

References (48)

1. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS
2. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations
3. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis 1. Clinical effects
4. Doubleblind, randomized, placebo-controlled study of oral high dose methylprednisolone in attacks of MS
5. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis
6. Optic Neuritis Treatment Trial: One-year follow-up results
7. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial
8. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis
9. Quantitative magnetic resonance imaging in multiple sclerosis: The effect of high dose intravenous methylprednisolone
10. Quantitative MRI changes in gadolinium-DTPA enhancement after highdose intravenous methylprednisolone in multiple sclerosis
11. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions
12. A correlative trial of gadolinium-DTPA MRI, EDSS and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone
13. The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: A longitudinal MRI study in relapsing-remitting multiple sclerosis patients
14. High-dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect
15. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
16. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions
17. Randomized trial comparing two different high doses of methylprednisolone in MS: A clinical and MRI study
18. Longitudinal MRI in multiple sclerosis: Correlation between disability and lesion burden
19. Relapsing-remitting multiple sclerosis: Longitudinal analysis of MR images-lack of correlation between changes in T2 lesion volume and clinical findings
20. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
21. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis
22. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study
23. Quantitative brain volumetric analysis from patients with multiple sclerosis: A follow-up study
24. Brain atrophy in relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis: Longitudinal quantitative analysis
25. Progressive cerebral atrophy in MS. A serial study using registered, volumetric MRI
26. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS
27. Histopathologic correlate of hypointense lesions on T1-weighted spin echo MRI in multiple sclerosis
28. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insight into substrates of disability
29. Effects of acute dehydration on computerised tomographic assessment of cerebral density and ventricular volume
30. Benign intracranial hypertension following corticosteroid withdrawal in childhood
31. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
32. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)
33. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines
34. Quantification of MRI lesion load in multiple sclerosis: A comparison of three computer-assisted techniques
35. Intra-observer reproducibility in measuring new MR putative markers of demyelination and axonal loss in multiple sclerosis: A comparison with conventional T2-weighted images
36. Detection of ventricular enlargement in patients at the earliest clinical stage of MS
37. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
38. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
39. A serial study of new MS lesions and the white matter from which they arise
40. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis
41. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: A serial diffusion MRI study
42. A longitudinal study of brain atrophy in relapsing-remitting multiple sclerosis
43. From enhancing lesions to brain atrophy in relapsing MS
44. Axonal damage in acute multiple sclerosis lesions
45. Axonal transection in the lesions of multiple sclerosis
46. Interaction of astrocytes and newly formed oligodendrocytes in resolving multiple sclerosis lesions
47. Acceleration in the rate of CNS remyelination in lysolecithin induced demy-elination
48. Remyelination in the human central nervous system